AEterna Zentaris (NASDAQ:AEZS) Shares Gap Down to $1.02

AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $1.01, but opened at $1.02. AEterna Zentaris shares last traded at $0.97, with a volume of 16,747 shares.

A number of equities analysts have weighed in on AEZS shares. ValuEngine raised AEterna Zentaris from a “hold” rating to a “buy” rating in a research report on Thursday, January 9th. Zacks Investment Research raised AEterna Zentaris from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research report on Tuesday, November 5th.

The business has a 50-day simple moving average of $1.12 and a two-hundred day simple moving average of $1.26. The stock has a market cap of $20.43 million, a price-to-earnings ratio of -1.60 and a beta of 1.17.

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of AEterna Zentaris during the 2nd quarter worth approximately $135,000. Virtu Financial LLC bought a new stake in shares of AEterna Zentaris during the 3rd quarter worth approximately $53,000. Sabby Management LLC raised its stake in shares of AEterna Zentaris by 486.1% during the 3rd quarter. Sabby Management LLC now owns 72,076 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 59,778 shares in the last quarter. Finally, Ikarian Capital LLC bought a new stake in shares of AEterna Zentaris during the 4th quarter worth approximately $107,000. Institutional investors own 9.10% of the company’s stock.

AEterna Zentaris Company Profile (NASDAQ:AEZS)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women’s health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Share:

Other News

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Canada News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Latest Headlines

Subscribe

Join our email list to receive the free market update newsletter

Canada News Group is a financial media company whose focus is to provide readers with financial news and content on the latest trends and happenings in the financial world.

error: Content is protected !!